Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8579408 | 0.86 | OPRM1 (0.73) | OPRM1DRD3KCNA3KCNH2 | |
| Hydrochloric Acid SCHEMBL9065401 | 0.85 | OPRM1 (0.72) | OPRM1DRD3KCNA3KCNH2 | |
| SCHEMBL9437085 | 0.82 | OPRM1 (0.65) | OPRM1DRD3 | |
| SCHEMBL9065208 | 0.80 | OPRM1 (0.65) | OPRM1DRD3KCNA3 | |
| SCHEMBL2722768 | 0.80 | SMN1; SMN2 (0.59) | OPRM1OPRL1 | |
| Sameridine SCHEMBL419071 | 0.80 | OPRM1 (1.00) | OPRM1DRD3KCNA3KCNH2 | |
| Hydrochloric Acid SCHEMBL9064512 | 0.80 | OPRM1 (0.75) | OPRM1KCNA3ADRA1AKCNH2 | |
| SCHEMBL9064765 | 0.79 | CHRM5 (0.64) | OPRM1OPRL1ADRA1AKCNH2 | |
| SCHEMBL20060916 | 0.77 | SMN1; SMN2 (0.65) | OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL8621179 | 0.76 | OPRM1 (0.56) | OPRM1OPRL1ADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096452-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2022-03-31 | — | — | US | disclosed |
| EP-0506778-B1 | SUBSTITUTED 4-PHENYL-4-PIPERIDINECARBOXAMIDES WITH BOTH LOCAL ANAESTHETIC AND ANALGESIC EFFECT AS WELL AS PROCESSES FOR THEIR PREPARATION | ASTRA AB (SE) | 1996-05-29 | — | — | EP | disclosed |
| US-5360805-A | Substituted 4-phenyl-4-piperidinecarboxamides with both local anaesthetic and analgesic effect as well as processes for their preparation | AKTIEBOLAGET ASTRA (SE) | 1994-11-01 | — | — | US | disclosed |
| US-5227389-A | SUBSTITUTED 4-PHENYL-4-PIPERIDINECARBOXAMIDES WITH BOTH LOCAL ANAESTHETIC AND ANALGESIC EFFECT AS WELL AS PROCESSES FOR THEIR PREPARATION | AKTIEBOLAGET ASTRA (SE) | 1993-07-13 | — | — | US | disclosed |
| WO-1991009845-A1 | SUBSTITUTED 4-PHENYL-4-PIPERIDINECARBOXAMIDES WITH BOTH LOCAL ANAESTHETIC AND ANALGESIC EFFECT AS WELL AS PROCESSES FOR THEIR PREPARATION | AKTIEBOLAGET ASTRA (SE) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096452-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | FABP7, ALB, SLC1A2 | OPRM1 304/4885DRD3 1240/4885KCNA3 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.